BioSpace

GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy

Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.

By BioSpace

1 min read
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights